Evolution of the concept of androgen-sensitive bladder cancer

References

• Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305:2295–303.
   PubMed Web of Science ®Google Scholar
• Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, et al. Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745–55.
   PubMed Web of Science ®Google Scholar
• Gakis G, Schilling D, Bedke J, Sievert KD, Stenzl A. Incidental prostate cancer at radical cystoprostatectomy: implications for apex-sparing surgery. BJU Int 2010;105:468–71.
   PubMed Web of Science ®Google Scholar
• Gakis G, Stenzl A, Renninger M. Do we use the right criteria for determining the clinical significance of incidental prostate cancer at radical cystoprostatectomy? Scand J Urol Nephrol 2012; Epub ahead of print.
   Google Scholar
• Mir C, Shariat SF, van der Kwast TH, Ashfaq R, Lotan Y, Evans A, et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int 2011;108:24–30.
   PubMed Web of Science ®Google Scholar
• Boorjian S, Heemers HV, Mongan NP, Farmer SA, Schmidt LJ, Sebo TJ, et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 2004;64:383–8.
   PubMed Web of Science ®Google Scholar
• Beilin J, Ball EM, Favaloro JM, Zajac JD. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J Mol Endocrinol 2000;25:85–96.
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 2007;99:558–68.
   PubMed Web of Science ®Google Scholar
• Izumi K, Zheng Y, Hsu JW, Chang C, Miyamoto H. Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: A potential mechanism of androgen-induced bladder carcinogenesis. Mol Carcinog 2011; doi: 10.1002/mc.21833; Epub ahead of print.
   Google Scholar
• Chu LW, Meyer TE, Li Q, Menashe I, Yu K, Rosenberg PS, et al. Association between genetic variants in the 8q24 cancer risk regions and circulating levels of androgens and sex hormone-binding globulin. Cancer Epidemiol Biomarkers Prev 2010;19:1848–54.
   PubMed Web of Science ®Google Scholar
• Ishak MB, Giri VN. A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies. Cancer Epidemiol Biomarkers Prev 2011;20:1599–610.
   PubMed Web of Science ®Google Scholar
• Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, Matullo G, et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 2009;41:991–5.
   PubMed Web of Science ®Google Scholar
• Bahrenberg G, Brauers A, Joost HG, Jakse G. Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. Biochem Biophys Res Commun 2000;275:783–8.
   PubMed Web of Science ®Google Scholar
• Jain A, Lam A, Vivanco I, Carey MF, Reiter RE. Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol Endocrinol 2002;16:2323–37.
   PubMedGoogle Scholar
• Zhigang Z, Wenlu S. Flutamide reduced prostate cancer development and prostate stem cell antigen mRNA expression in high grade prostatic intraepithelial neoplasia. Int J Cancer 2008;122:864–70.
   PubMed Web of Science ®Google Scholar
• Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000;19:1288–96.
   PubMed Web of Science ®Google Scholar
• Saeki N, Gu J, Yoshida T, Wu X. Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res 2010;16:3533–8.
   PubMed Web of Science ®Google Scholar
• Wang S, Tang J, Wang M, Yuan L, Zhang Z. Genetic variation in PSCA and bladder cancer susceptibility in a Chinese population. Carcinogenesis 2010;31:621–4.
   PubMed Web of Science ®Google Scholar
• Joung JY, Lee YS, Park S, Yoon H, Lee SJ, Park WS, et al. Haplotype analysis of prostate stem cell antigen and association with prostate cancer risk. J Urol 2011;185:2112–18.
   PubMed Web of Science ®Google Scholar
• Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, et al. Androgen deprivation causes epithelial–mesenchymal transition in the prostate: implications for androgen-deprivation Therapy. Cancer Res 2012;72:527–36.
   PubMed Web of Science ®Google Scholar
• Kauffman EC, Robinson BD, Downes MJ, Powell LG, Lee MM, Scherr DS, et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog 2011;501:931–44.
   Google Scholar
• Metzger E, Wissmann M, Yin N, Müller JM, Schneider R, Peters AH, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005;437:436–9.
   PubMed Web of Science ®Google Scholar
• Miyake H, Hara I, Yamanaka K, Muramaki M, Eto H. Prognostic significance of insulin-like growth factor (IGF) binding protein-2 to IGF-binding protein-3 ratio in patients undergoing radical cystectomy for invasive transitional cell carcinoma of the bladder. BJU Int 2005;95:987–91.
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011;378:1812–23.
   PubMed Web of Science ®Google Scholar
• Gakis G, Schwentner C, Todenhoefer T, Stenzl A. Current status of molecular markers for prognostication and outcome in invasive bladder cancer. BJU Int 2012;110:233–7.
   Google Scholar